APO Research
Talk to an analyst

APO RESEARCH · REPORT

Glycopeptide Antibiotics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Glycopeptide Antibiotics Market Outlook and Growth Opportunities 2026

2 January 2026191 pages

Choose your research edition.

Industry ResearchGlycopeptide Antibiotics Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Glycopeptide Antibiotics Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Glycopeptide Antibiotics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Glycopeptide Antibiotics Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Glycopeptide Antibiotics Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Glycopeptide Antibiotics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Glycopeptide Antibiotics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Glycopeptide Antibiotics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Glycopeptide Antibiotics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Glycopeptide Antibiotics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Glycopeptide Antibiotics market include Allergan, Alvogen, ANI Pharmaceuticals, Aurobindo Pharma, Hikma Pharmaceuticals plc, Lytix Biopharma, Theravance Biopharma, Eli Lilly and Company and Shenwei Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Glycopeptide Antibiotics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Glycopeptide Antibiotics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Glycopeptide Antibiotics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Glycopeptide Antibiotics market.

Glycopeptide Antibiotics Segment by Company

Allergan

Alvogen

ANI Pharmaceuticals

Aurobindo Pharma

Hikma Pharmaceuticals plc

Lytix Biopharma

Theravance Biopharma

Eli Lilly and Company

Shenwei Pharmaceutical

Zhejiang Hisun Pharmaceutical Co., Ltd.

Glycopeptide Antibiotics Segment by Type

Vancomycin

Teicoplanin

Bleomycin

Glycopeptide Antibiotics Segment by Application

Enterococcus Treatment

Staphylococcus Aureus Treatment

Glycopeptide Antibiotics Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Glycopeptide Antibiotics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Glycopeptide Antibiotics key companies, revenue, market share, and recent developments.

3. To split the Glycopeptide Antibiotics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Glycopeptide Antibiotics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Glycopeptide Antibiotics significant trends, drivers, influence factors in global and regions.

6. To analyze Glycopeptide Antibiotics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Glycopeptide Antibiotics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Glycopeptide Antibiotics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Glycopeptide Antibiotics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Glycopeptide Antibiotics industry.

Chapter 3: Detailed analysis of Glycopeptide Antibiotics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Glycopeptide Antibiotics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Glycopeptide Antibiotics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Glycopeptide Antibiotics Industry Trends Table 2. Glycopeptide Antibiotics Industry Drivers Table 3. Glycopeptide Antibiotics Industry Opportunities and Challenges Table 4. Glycopeptide Antibiotics Industry Restraints Table 5. Global Glycopeptide Antibiotics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Glycopeptide Antibiotics Revenue Share by Company (2021-2026) Table 7. Global Glycopeptide Antibiotics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Glycopeptide Antibiotics Key Company Manufacturing Base & Headquarters Table 9. Global Glycopeptide Antibiotics Company, Product Type & Application Table 10. Global Glycopeptide Antibiotics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Glycopeptide Antibiotics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Vancomycin Table 15. Significant Companies of Teicoplanin Table 16. Significant Companies of Bleomycin Table 17. Global Glycopeptide Antibiotics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Glycopeptide Antibiotics Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Glycopeptide Antibiotics Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Glycopeptide Antibiotics Sales Value Share by Type (2021-2026) Table 21. Global Glycopeptide Antibiotics Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Enterococcus Treatment Table 23. Significant Companies of Staphylococcus Aureus Treatment Table 24. Global Glycopeptide Antibiotics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Glycopeptide Antibiotics Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Glycopeptide Antibiotics Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Glycopeptide Antibiotics Sales Value Share by Application (2021-2026) Table 28. Global Glycopeptide Antibiotics Sales Value Share by Application (2027-2032) Table 29. Global Glycopeptide Antibiotics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Glycopeptide Antibiotics Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Glycopeptide Antibiotics Sales Value Share by Region (2021-2026) Table 32. Global Glycopeptide Antibiotics Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Glycopeptide Antibiotics Sales Value Share by Region (2027-2032) Table 34. Global Glycopeptide Antibiotics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Glycopeptide Antibiotics Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Glycopeptide Antibiotics Sales Value Market Share by Country (2021-2026) Table 37. Global Glycopeptide Antibiotics Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Glycopeptide Antibiotics Sales Value Market Share by Country (2027-2032) Table 39. Allergan Company Information Table 40. Allergan Business Overview Table 41. Allergan Glycopeptide Antibiotics Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Allergan Glycopeptide Antibiotics Product Portfolio Table 43. Allergan Recent Development Table 44. Alvogen Company Information Table 45. Alvogen Business Overview Table 46. Alvogen Glycopeptide Antibiotics Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Alvogen Glycopeptide Antibiotics Product Portfolio Table 48. Alvogen Recent Development Table 49. ANI Pharmaceuticals Company Information Table 50. ANI Pharmaceuticals Business Overview Table 51. ANI Pharmaceuticals Glycopeptide Antibiotics Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. ANI Pharmaceuticals Glycopeptide Antibiotics Product Portfolio Table 53. ANI Pharmaceuticals Recent Development Table 54. Aurobindo Pharma Company Information Table 55. Aurobindo Pharma Business Overview Table 56. Aurobindo Pharma Glycopeptide Antibiotics Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Aurobindo Pharma Glycopeptide Antibiotics Product Portfolio Table 58. Aurobindo Pharma Recent Development Table 59. Hikma Pharmaceuticals plc Company Information Table 60. Hikma Pharmaceuticals plc Business Overview Table 61. Hikma Pharmaceuticals plc Glycopeptide Antibiotics Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Hikma Pharmaceuticals plc Glycopeptide Antibiotics Product Portfolio Table 63. Hikma Pharmaceuticals plc Recent Development Table 64. Lytix Biopharma Company Information Table 65. Lytix Biopharma Business Overview Table 66. Lytix Biopharma Glycopeptide Antibiotics Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Lytix Biopharma Glycopeptide Antibiotics Product Portfolio Table 68. Lytix Biopharma Recent Development Table 69. Theravance Biopharma Company Information Table 70. Theravance Biopharma Business Overview Table 71. Theravance Biopharma Glycopeptide Antibiotics Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Theravance Biopharma Glycopeptide Antibiotics Product Portfolio Table 73. Theravance Biopharma Recent Development Table 74. Eli Lilly and Company Company Information Table 75. Eli Lilly and Company Business Overview Table 76. Eli Lilly and Company Glycopeptide Antibiotics Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Eli Lilly and Company Glycopeptide Antibiotics Product Portfolio Table 78. Eli Lilly and Company Recent Development Table 79. Shenwei Pharmaceutical Company Information Table 80. Shenwei Pharmaceutical Business Overview Table 81. Shenwei Pharmaceutical Glycopeptide Antibiotics Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Shenwei Pharmaceutical Glycopeptide Antibiotics Product Portfolio Table 83. Shenwei Pharmaceutical Recent Development Table 84. Zhejiang Hisun Pharmaceutical Co., Ltd. Company Information Table 85. Zhejiang Hisun Pharmaceutical Co., Ltd. Business Overview Table 86. Zhejiang Hisun Pharmaceutical Co., Ltd. Glycopeptide Antibiotics Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Zhejiang Hisun Pharmaceutical Co., Ltd. Glycopeptide Antibiotics Product Portfolio Table 88. Zhejiang Hisun Pharmaceutical Co., Ltd. Recent Development Table 89. Research Programs/Design for This Report Table 90. Authors List of This Report Table 91. Secondary Sources Table 92. Primary Sources List of Figures Figure 1. Glycopeptide Antibiotics Product Image Figure 2. Global Glycopeptide Antibiotics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Glycopeptide Antibiotics Market Size (2021-2032) & (US$ Million) Figure 4. Global Glycopeptide Antibiotics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Vancomycin Image Figure 8. Teicoplanin Image Figure 9. Bleomycin Image Figure 10. Global Glycopeptide Antibiotics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Glycopeptide Antibiotics Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Glycopeptide Antibiotics Sales Value Share by Type (2021-2032) Figure 13. Enterococcus Treatment Image Figure 14. Staphylococcus Aureus Treatment Image Figure 15. Global Glycopeptide Antibiotics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Glycopeptide Antibiotics Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Glycopeptide Antibiotics Sales Value Share by Application (2021-2032) Figure 18. Global Glycopeptide Antibiotics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Glycopeptide Antibiotics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Glycopeptide Antibiotics Sales Value (2021-2032) & (US$ Million) Figure 21. North America Glycopeptide Antibiotics Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Glycopeptide Antibiotics Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Glycopeptide Antibiotics Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Glycopeptide Antibiotics Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Glycopeptide Antibiotics Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Glycopeptide Antibiotics Sales Value (2021-2032) & (US$ Million) Figure 27. South America Glycopeptide Antibiotics Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Glycopeptide Antibiotics Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Glycopeptide Antibiotics Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Vancomycin
  • Teicoplanin
  • Bleomycin
Applications
  • Enterococcus Treatment
  • Staphylococcus Aureus Treatment
Companies covered
  • Allergan
  • Alvogen
  • ANI Pharmaceuticals
  • Aurobindo Pharma
  • Hikma Pharmaceuticals plc
  • Lytix Biopharma
  • Theravance Biopharma
  • Eli Lilly and Company
  • Shenwei Pharmaceutical
  • Zhejiang Hisun Pharmaceutical Co., Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Glycopeptide Antibiotics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Glycopeptide Antibiotics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Glycopeptide Antibiotics Market Dynamics
  1. 2.1 Glycopeptide Antibiotics Industry Trends
  2. 2.2 Glycopeptide Antibiotics Industry Drivers
  3. 2.3 Glycopeptide Antibiotics Industry Opportunities and Challenges
  4. 2.4 Glycopeptide Antibiotics Industry Restraints
3 Glycopeptide Antibiotics Market by Company
  1. 3.1 Global Glycopeptide Antibiotics Company Revenue Ranking in 2025
  2. 3.2 Global Glycopeptide Antibiotics Revenue by Company (2021-2026)
  3. 3.3 Global Glycopeptide Antibiotics Company Ranking (2024-2026)
  4. 3.4 Global Glycopeptide Antibiotics Company Manufacturing Base and Headquarters
  5. 3.5 Global Glycopeptide Antibiotics Company Product Type and Application
  6. 3.6 Global Glycopeptide Antibiotics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Glycopeptide Antibiotics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Glycopeptide Antibiotics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Glycopeptide Antibiotics Market by Type
  1. 4.1 Glycopeptide Antibiotics Type Introduction
  2. 4.1.1 Vancomycin
  3. 4.1.2 Teicoplanin
  4. 4.1.3 Bleomycin
  5. 4.2 Global Glycopeptide Antibiotics Sales Value by Type
  6. 4.2.1 Global Glycopeptide Antibiotics Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Glycopeptide Antibiotics Sales Value by Type (2021-2032)
  8. 4.2.3 Global Glycopeptide Antibiotics Sales Value Share by Type (2021-2032)
5 Glycopeptide Antibiotics Market by Application
  1. 5.1 Glycopeptide Antibiotics Application Introduction
  2. 5.1.1 Enterococcus Treatment
  3. 5.1.2 Staphylococcus Aureus Treatment
  4. 5.2 Global Glycopeptide Antibiotics Sales Value by Application
  5. 5.2.1 Global Glycopeptide Antibiotics Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Glycopeptide Antibiotics Sales Value by Application (2021-2032)
  7. 5.2.3 Global Glycopeptide Antibiotics Sales Value Share by Application (2021-2032)
6 Glycopeptide Antibiotics Regional Value Analysis
  1. 6.1 Global Glycopeptide Antibiotics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Glycopeptide Antibiotics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Glycopeptide Antibiotics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Glycopeptide Antibiotics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Glycopeptide Antibiotics Sales Value (2021-2032)
  7. 6.3.2 North America Glycopeptide Antibiotics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Glycopeptide Antibiotics Sales Value (2021-2032)
  10. 6.4.2 Europe Glycopeptide Antibiotics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Glycopeptide Antibiotics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Glycopeptide Antibiotics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Glycopeptide Antibiotics Sales Value (2021-2032)
  16. 6.6.2 South America Glycopeptide Antibiotics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Glycopeptide Antibiotics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Glycopeptide Antibiotics Sales Value Share by Country, 2025 VS 2032
7 Glycopeptide Antibiotics Country-level Value Analysis
  1. 7.1 Global Glycopeptide Antibiotics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Glycopeptide Antibiotics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Glycopeptide Antibiotics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Glycopeptide Antibiotics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Glycopeptide Antibiotics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Glycopeptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Glycopeptide Antibiotics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Allergan
  2. 8.1.1 Allergan Company Information
  3. 8.1.2 Allergan Business Overview
  4. 8.1.3 Allergan Glycopeptide Antibiotics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Allergan Glycopeptide Antibiotics Product Portfolio
  6. 8.1.5 Allergan Recent Developments
  7. 8.2 Alvogen
  8. 8.2.1 Alvogen Company Information
  9. 8.2.2 Alvogen Business Overview
  10. 8.2.3 Alvogen Glycopeptide Antibiotics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Alvogen Glycopeptide Antibiotics Product Portfolio
  12. 8.2.5 Alvogen Recent Developments
  13. 8.3 ANI Pharmaceuticals
  14. 8.3.1 ANI Pharmaceuticals Company Information
  15. 8.3.2 ANI Pharmaceuticals Business Overview
  16. 8.3.3 ANI Pharmaceuticals Glycopeptide Antibiotics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 ANI Pharmaceuticals Glycopeptide Antibiotics Product Portfolio
  18. 8.3.5 ANI Pharmaceuticals Recent Developments
  19. 8.4 Aurobindo Pharma
  20. 8.4.1 Aurobindo Pharma Company Information
  21. 8.4.2 Aurobindo Pharma Business Overview
  22. 8.4.3 Aurobindo Pharma Glycopeptide Antibiotics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Aurobindo Pharma Glycopeptide Antibiotics Product Portfolio
  24. 8.4.5 Aurobindo Pharma Recent Developments
  25. 8.5 Hikma Pharmaceuticals plc
  26. 8.5.1 Hikma Pharmaceuticals plc Company Information
  27. 8.5.2 Hikma Pharmaceuticals plc Business Overview
  28. 8.5.3 Hikma Pharmaceuticals plc Glycopeptide Antibiotics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Hikma Pharmaceuticals plc Glycopeptide Antibiotics Product Portfolio
  30. 8.5.5 Hikma Pharmaceuticals plc Recent Developments
  31. 8.6 Lytix Biopharma
  32. 8.6.1 Lytix Biopharma Company Information
  33. 8.6.2 Lytix Biopharma Business Overview
  34. 8.6.3 Lytix Biopharma Glycopeptide Antibiotics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Lytix Biopharma Glycopeptide Antibiotics Product Portfolio
  36. 8.6.5 Lytix Biopharma Recent Developments
  37. 8.7 Theravance Biopharma
  38. 8.7.1 Theravance Biopharma Company Information
  39. 8.7.2 Theravance Biopharma Business Overview
  40. 8.7.3 Theravance Biopharma Glycopeptide Antibiotics Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Theravance Biopharma Glycopeptide Antibiotics Product Portfolio
  42. 8.7.5 Theravance Biopharma Recent Developments
  43. 8.8 Eli Lilly and Company
  44. 8.8.1 Eli Lilly and Company Company Information
  45. 8.8.2 Eli Lilly and Company Business Overview
  46. 8.8.3 Eli Lilly and Company Glycopeptide Antibiotics Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Eli Lilly and Company Glycopeptide Antibiotics Product Portfolio
  48. 8.8.5 Eli Lilly and Company Recent Developments
  49. 8.9 Shenwei Pharmaceutical
  50. 8.9.1 Shenwei Pharmaceutical Company Information
  51. 8.9.2 Shenwei Pharmaceutical Business Overview
  52. 8.9.3 Shenwei Pharmaceutical Glycopeptide Antibiotics Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Shenwei Pharmaceutical Glycopeptide Antibiotics Product Portfolio
  54. 8.9.5 Shenwei Pharmaceutical Recent Developments
  55. 8.10 Zhejiang Hisun Pharmaceutical Co., Ltd.
  56. 8.10.1 Zhejiang Hisun Pharmaceutical Co., Ltd. Company Information
  57. 8.10.2 Zhejiang Hisun Pharmaceutical Co., Ltd. Business Overview
  58. 8.10.3 Zhejiang Hisun Pharmaceutical Co., Ltd. Glycopeptide Antibiotics Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Zhejiang Hisun Pharmaceutical Co., Ltd. Glycopeptide Antibiotics Product Portfolio
  60. 8.10.5 Zhejiang Hisun Pharmaceutical Co., Ltd. Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst